Versant Venture Capital VI, L.P.
CIK 1687880 · last filed 2025-08-26
Versant Venture Capital VI, L.P. is a corporate insider who has filed 27 SEC Form 4 insider transactions across 7 companies since 2019. The most recent filing shows the insider sold $66.8M of LENZ on Aug 26, 2025. Across all open-market trades the lifetime net is −$98.3M, making them a net seller over the disclosed history. Current disclosed insider exposure totals $47.9M across reported positions.
"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.
$47.91M
7
27
-$98.34M
Holdings By Company
| Symbol | Role | Shares | Price | Disclosed Exposure | Lifetime OM Net | Filings | Latest Filed |
|---|---|---|---|---|---|---|---|
| LENZ | 10%+ Owner | 2,299,292 | $5.84 | $13.44M | -$216.73M | 3 | 2025-08-26 |
| IPSC | 10%+ Owner | 13,259,905 | $2.02 | $26.85M | $0 | 1 | 2021-12-28 |
| LENZ Therapeutics, Inc. (GRPH) Delisted | 10%+ Owner | 2,319,446 | $22.26 | $51.63M | $18.36M | 1 | 2021-07-01 |
| BDTX | 10%+ Owner | 4,343,210 | $1.75 | $7.62M | $39.27M | 9 | 2020-11-25 |
| Pandion Therapeutics, Inc. (PAND) Delisted | 10%+ Owner | 3,754,051 | $60.05 | $225.43M | $0 | 1 | 2020-07-21 |
| Akero Therapeutics, Inc. (AKRO) Delisted | 10%+ Owner | 7,297,318 | $54.65 | $398.80M | -$24.20M | 8 | 2020-07-10 |
| Oyster Point Pharma, Inc. (OYST) Delisted | 10%+ Owner | 2,945,158 | $11.17 | $32.90M | $84.96M | 1 | 2019-11-04 |
Recent Filings
27 filings| Filed | Symbol | Action | Net Shares | Net $ | Link |
|---|---|---|---|---|---|
| 2025-08-26 | LENZ | Sell (S) | −1,692,846 | -$66.82M | EDGAR |
| 2025-07-14 | LENZ | Sell (S) | −1,722,384 | -$58.56M | EDGAR |
| 2025-06-12 | LENZ | Sell (S) | −3,150,000 | -$91.35M | EDGAR |
| 2024-08-13 | TPST | Notice (144) | −387,999 | -$427.0K | EDGAR |
| 2024-08-09 | TPST | Notice (144) | −400,000 | -$7.21M | EDGAR |
| 2024-03-25 | — | Other (J) | +5,383,827 | $0 | |
| 2021-12-28 | IPSC | Other (J) | −2,226,024 | $0 | EDGAR |
| 2021-07-01 | LENZ Therapeutics, Inc. (GRPH) Delisted | Mixed | +84,308,676 | $18.36M | EDGAR |
| 2020-11-25 | BDTX | Other (J) | −3,047,652 | $0 | EDGAR |
| 2020-11-23 | BDTX | Sell (S) | −520,068 | -$17.17M | EDGAR |
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.